RBC Capital on Karyopharm Therapeutics (KPTI): 'See Buying Oppty On Weakness'

July 21, 2026 7:56 AM

RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $16.00 price target on Karyopharm Therapeutics (NASDAQ: KPTI).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found